Corvus Pharmaceuticals, Inc. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
Corvus Pharmaceuticals, Inc. (CRVS) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $25.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2025-03-25
- Corvus Pharmaceuticals, Inc. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2024 was $25.00K.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|
| 2024-12-31 | $25.00K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |